Yahoo · Oct 19, 2026
Here's How Tempus AI Demonstrates Improving Operating Leverage
TEM shows improving operating leverage as Q2 revenues jump 22%, adjusted EBITDA turns positive and lower interest costs support its free cash flow goal.
IN
NASDAQ · INSP
Inspire Medical Systems, Inc.
Healthcare · Medical - Devices
$68.10
Down-$3.08 (-4.33%)
Updated Oct 31, 2026, 8:47 PM
SID Score
4.0/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.05B
- P/E ratio
- 76.09
- Dividend yield
- 0.00%
- 52-week range
- $38.91 – $147.03
- Volume
- 796.4K
- Avg. volume
- 1.3M
Price performance · INSP
INSP price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
INSP closed at $68.10 after 21 trading sessions, down 2.67% for the selected period.
- Last close
- $68.10
- Period change
- -2.67%
- Period low
- $66.69
- Period high
- $72.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $70.63 | $71.195 | $67.80 | $68.10 | 796.4K |
| Oct 29, 2026 | $71.85 | $71.85 | $70.54 | $71.18 | 512.57K |
| Oct 28, 2026 | $71.25 | $71.99 | $70.15 | $70.97 | 367.1K |
| Oct 27, 2026 | $71.16 | $71.59 | $69.32 | $71.30 | 667.72K |
| Oct 26, 2026 | $70.51 | $72.40 | $70.00 | $71.01 | 528.47K |
| Oct 23, 2026 | $72.25 | $72.75 | $68.4391 | $71.11 | 592.14K |
| Oct 22, 2026 | $70.50 | $73.29 | $70.50 | $72.66 | 659.84K |
| Oct 21, 2026 | $70.84 | $72.50 | $70.40 | $71.07 | 554.25K |
| Oct 20, 2026 | $71.01 | $71.90 | $70.00 | $71.34 | 1.05M |
| Oct 19, 2026 | $68.73 | $70.28 | $68.44 | $70.15 | 656.15K |
| Oct 16, 2026 | $70.40 | $71.25 | $68.54 | $68.79 | 494.54K |
| Oct 15, 2026 | $68.72 | $70.40 | $68.33 | $70.12 | 621.18K |
| Oct 14, 2026 | $69.33 | $69.57 | $67.41 | $68.07 | 855.15K |
| Oct 13, 2026 | $71.37 | $72.46 | $68.62 | $68.86 | 1.04M |
| Oct 12, 2026 | $69.99 | $72.01 | $69.41 | $71.49 | 1.01M |
| Oct 9, 2026 | $67.20 | $69.73 | $66.83 | $68.89 | 867.34K |
| Oct 8, 2026 | $67.12 | $68.00 | $66.07 | $66.69 | 846.71K |
| Oct 7, 2026 | $67.13 | $68.37 | $66.50 | $67.45 | 1.48M |
| Oct 6, 2026 | $71.23 | $71.86 | $67.99 | $68.20 | 869.55K |
| Oct 5, 2026 | $69.66 | $71.36 | $68.6731 | $70.75 | 632.11K |
| Oct 2, 2026 | $71.74 | $71.74 | $68.44 | $69.97 | 761.93K |
Latest INSP news
The latest Smart Investors Daily articles mentioning INSP.
Stock researchCompany · Overview
Company
Market Activity
Research & News
INSP research
Overview
Company profile and research snapshot.
Company profile
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $139.92
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | Truist Securities | Hold | — |
| Oct 7, 2026 | Barclays | Underweight | — |
| Oct 2, 2026 | Freedom Capital Markets | Buy | — |
| Oct 1, 2026 | RBC Capital | Sector Perform | — |
| Sep 21, 2026 | Freedom Capital Markets | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 14, 2026
Truist Securities Maintains Hold on Inspire Medical Systems, Raises Price Target to $78
Truist Securities analyst Richard Newitter maintains Inspire Medical Systems (NYSE:INSP) with a Hold and raises the price target from $62 to $78.
Yahoo · Oct 12, 2026
Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer
BURLINGTON, Mass., October 12, 2026--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Mary-Katherine ("Katie") McClure as Chief Commercial Officer effective October 12, 2026, succeeding Micah Mitchell, who will be departing following a leadership transition period.
Fintel · Oct 7, 2026
Barclays Initiates Coverage of Inspire Medical Systems at Underweight
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
